SolarCity Corp. (SCTY) Financials Nov 14, 2014, 7:51

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
SolarCity Corp. (SCTY) Financials Nov 14, 2014, 7:51 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for SolarCity Corp.


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 32.65M 32.43M 59.55M 126.91M 163.84M
Cost of Goods Sold (COGS) incl. D&A 30.88M 30.14M 47.14M 99.45M 124.47M
COGS excluding D&A 27.65M 24.41M 34.8M 78.64M 83.02M
Depreciation & Amortization Expense 3.23M 5.73M 12.34M 20.81M 41.45M
Depreciation - - - - -
Amortization of Intangibles - - - - -
Gross Income 1.77M 2.28M 12.42M 27.46M 39.37M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 21.77M 41.63M 73.67M 118.47M 187.25M
Research & Development 0 0 0 0 0
Other SG&A 21.77M 41.63M 73.67M 118.47M 187.25M
Other Operating Expense 0 0 0 0 500,000
Unusual Expense 2.23M 2M 2.05M 0 1.8M
EBIT after Unusual Expense (2.23M) (2M) (2.05M) 0 (1.8M)
Non Operating Income/Expense (133,000) (763,000) (1.05M) (2.52M) (641,000)
Non-Operating Interest Income 0 0 0 0 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 334,000 4.9M 9.27M 20.14M 25.74M
Gross Interest Expense 334,000 4.9M 9.27M 20.14M 25.74M
Interest Capitalized 0 0 0 - -
Pretax Income (22.7M) (47.01M) (73.62M) (113.67M) (176.56M)
Income Tax 22,000 65,000 92,000 54,000 (24.8M)
Income Tax - Current Domestic - - 81,000 26,000 90,000
Income Tax - Current Foreign - - 4,000 15,000 26,000
Income Tax - Deferred Domestic - - 7,000 13,000 (24.92M)
Income Tax - Deferred Foreign - - 0 0 0
Income Tax Credits - - 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 2.23M 2M 2.05M 0 0
Consolidated Net Income (20.49M) (45.08M) (71.66M) (113.73M) (151.76M)
Minority Interest Expense 3.51M (8.46M) (117.23M) (14.39M) (95.97M)
Net Income (24M) (36.62M) 45.57M (99.34M) (55.79M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (24M) (36.62M) 45.57M (99.34M) (55.79M)
Preferred Dividends 0 0 0 10.09M 0
Net Income Available to Common (24M) (36.62M) 45.57M (109.43M) (55.79M)
EPS (Basic) (0.49) (0.74) 0.90 (7.68) (0.70)
Basic Shares Outstanding 49.3M 49.5M 50.9M 14.24M 79.78M
EPS (Diluted) (0.49) (0.74) 0.82 (7.69) (0.70)
Diluted Shares Outstanding 49.3M 49.5M 55.44M 14.27M 79.78M
EBITDA (16.77M) (33.61M) (48.92M) (70.2M) (106.93M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading